Edinburgh Spin‑out BIOCAPTIVA Raises £1.58M, Launches msX in US

BIOCAPTIVA, a University of Edinburgh spin‑out, has closed a £1.58 million funding round and introduced its first product offering in the United States. The company debuted its msX magnetic bead kits for research use in Boston earlier this month as it begins building evidence across applications in oncology and genetic testing.

The startup's msX platform targets a persistent bottleneck in liquid biopsy workflows: preparing blood samples for reliable cell‑free DNA (cfDNA) analysis. By extracting DNA directly from whole blood without centrifugation or extra reagents, BIOCAPTIVA says the approach delivers higher‑quality samples with simpler and faster processing that can be automated.

That combination—reduced handling, quicker extraction and compatibility with larger sample volumes—could make liquid biopsy testing more scalable and accessible for researchers and diagnostic developers. For labs wrestling with variable sample prep, the promise is fewer steps, less equipment and more consistent input material for downstream sequencing and assays.

The latest raise was led by existing investor Archangels, with participation from Old College Capital, BBI, Scottish Enterprise and newcomer EverQuest Capital Partners. BIOCAPTIVA plans to channel the funding into R&D to broaden its product line and to validate performance across a wider set of use cases.

To support growth, the company appointed Alan Schafer as Chief Technology Officer. Schafer brings decades of experience in molecular diagnostics and genetics technologies, having held senior roles at Inivata, Population Genetics Technologies, 14M Genomics and GlaxoSmithKline.

Jeremy Wheeler, BIOCAPTIVA’s CEO, noted that while oncology teams have advanced analysis techniques, sample preparation has seen little step‑change. The msX launch and fresh capital aim to change that, with the goal of accelerating cancer research and improving outcomes at scale.